MNKD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MannKind Corp (MNKD) does not currently present a compelling buy opportunity for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock faces significant uncertainties, including declining financial performance, negative hedge fund sentiment, and potential risks to its royalty streams. While there are some positive catalysts, such as upcoming regulatory decisions, the overall risk/reward profile appears unfavorable at this time.
The stock's MACD is positive at 0.115, indicating a bullish trend, but the RSI at 73.098 is in the neutral zone, suggesting no clear overbought or oversold conditions. Moving averages are converging, and the stock is trading near its resistance level of 2.743. Pre-market price is 2.775, up 0.91%, but no strong technical breakout is evident.
and Furoscix ReadyFlow autoinjector (July 26, 2026), as well as developmental updates for MNKD-201 in IPF, could provide momentum if successful.
Hedge funds are aggressively selling, with a 337.78% increase in selling activity. Analysts have significantly lowered price targets due to concerns about the durability of Tyvaso DPI royalties, competition from United Therapeutics' soft mist inhaler, and declining financial performance. No recent insider or congress trading data suggests a lack of confidence from influential stakeholders.
In Q4 2025, revenue grew by 45.82% YoY to $111.96M, but net income dropped significantly to -$15.95M (-314.87% YoY). EPS declined to -0.05 (-266.67% YoY), and gross margin fell to 71.82% (-6.81% YoY). The company is facing profitability challenges despite revenue growth.
Analysts have recently lowered price targets significantly, with ratings ranging from Buy to Sector Perform. Concerns about Tyvaso DPI royalties and competition from United Therapeutics' soft mist inhaler dominate sentiment. However, some analysts see a favorable risk/reward if MannKind executes on its 2026 catalysts.
